logo
Plus   Neg
Share
Email

Merck: FDA Approves KEYTRUDA-Inlyta Combination - Quick Facts

Merck (MRK) announced the U.S. FDA has approved KEYTRUDA in combination with Inlyta for the first-line treatment of patients with advanced renal cell carcinoma. Inlyta (axitinib) is a tyrosine kinase inhibitor.

The approval was based on data from the pre-specified interim analysis of a phase 3 KEYNOTE-426 trial, where KEYTRUDA-axitinib combination reduced the risk of death by nearly half compared to Sunitinib. The KEYNOTE-426 trial also showed significant improvements in overall survival, progression-free survival and objective response rate for the KEYTRUDA-axitinib combination compared to sunitini.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Alibaba is upgrading its intellectual property system using blockchain technology, according to local news outlet Sohu. Alibaba Platform Management expects this to benefit mainly small and medium-sized enterprises, brands and entrepreneurs. The technology will be fully implemented in September, and thereafter, the company intends to expand it to the field of digital copyright protection. Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020. While reporting financial results for the second quarter on Thursday, Hormel Foods Corp. (HRL) lowered its earnings and net sales guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $1.71 to $1.85 per share, and net sales between $9.70 billion and $10.20...
Follow RTT